India may be showing signs that it no longer wants to be Big Pharma’s public enemy No. 1.
In an about-face, the Indian Patent Office has granted a patent to Gilead Sciences for its Sovaldi drug, which treats hepatitis C. Last year, the same office rejected the company’s patent application after a challenge was filed by patient advocacy groups and companies that make pharmaceutical ingredients. At that time, India’s patent office said Sovaldi, whose generic name is sofosbuvir, was not a significant improvement over an earlier compound developed by another company. Gilead appealed that ruling.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
